Jiangsu Chia Tai Fenghai Pharma (CTFH) signed a $200 million agreement with Insilico Medicine, an AI drug discovery company headquartered in Hong Kong, to discover two triple-negative breast cancer candidates, aiming at previously undruggable targets. In September, Insilico raised $37 million from China investors after publishing an article in Nature Biotechnology showing its AI-platform could generate, synthesize and preclinically validate a series of compounds in 46 days. CTFH, which said it hopes the collaboration will become a long-term relationship, will make milestone payments and pay royalties on the candidates.
Source: China Biotoday
